Action Point Financial Planning’s Vir Biotechnology VIR Stock Holding History

Action Point Financial Planning’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.1K	Buy	+2,860	New	+$27.2K	﹤0.01%	1000

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Action Point Financial Planning's VIR Position: Q2 2026 in Review

Action Point Financial Planning opened a new position in Vir Biotechnology (VIR) in Q2 2026: 2,860 shares worth $29.1K. The stake represents ﹤0.01% of the portfolio and ranks #1000 among its holdings.

236 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Action Point Financial Planning held 2,860 shares of Vir Biotechnology worth $29.1K as of Q2 2026.
Vir Biotechnology was a new Action Point Financial Planning position in Q2 2026.
Vir Biotechnology made up ﹤0.01% of Action Point Financial Planning's portfolio in Q2 2026, its #1000 holding.
236 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Action Point Financial Planning's 13F filing for Q2 2026, filed 14 Aug 2026.